Get started
EXELIXIS INC EXELIXIS INC EXELIXIS INC

EXELIXIS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

EX9 chart


Full chart

EX9 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪9.97 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
21.82
Basic EPS (TTM)
1.75 EUR
Net income (FY)
‪503.53 M‬ EUR
Revenue (FY)
‪2.09 B‬ EUR
Shares float
‪271.98 M‬
Beta (1Y)
0.06

Employees


Employees (FY)
‪1.15 K‬
Change (1Y)
−163 −12.44%
Revenue / Employee (1Y)
‪1.83 M‬ EUR
Net income / Employee (1Y)
‪439.00 K‬ EUR

About Exelixis, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael M. Morrissey
Website
exelixis.com
Headquarters
Alameda
Founded
1994
FIGI
BBG000BL3426
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EX9 news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where EX9 is featured.

See all sparks 



Frequently Asked Questions


The current price of EX9 is 35.48 EUR — it has increased by 2.04% in the past 24 hours. Watch EXELIXIS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange EXELIXIS INC stocks are traded under the ticker EX9.
EX9 stock has fallen by −2.77% compared to the previous week, the month change is a 12.08% rise, over the last year EXELIXIS INC has showed a 74.69% increase.
We've gathered analysts' opinions on EXELIXIS INC future price: according to them, EX9 price has a max estimate of 42.92 EUR and a min estimate of 21.94 EUR. Watch EX9 chart and read a more detailed EXELIXIS INC stock forecast: see what analysts think of EXELIXIS INC and suggest that you do with its stocks.
EX9 reached its all-time high on Mar 3, 2025 with the price of 38.28 EUR, and its all-time low was 13.60 EUR and was reached on Jul 19, 2021. View more price dynamics on EX9 chart.
See other stocks reaching their highest and lowest prices.
EX9 stock is 2.73% volatile and has beta coefficient of 0.06. Track EXELIXIS INC stock price on the chart and check out the list of the most volatile stocks — is EXELIXIS INC there?
Today EXELIXIS INC has the market capitalization of ‪10.12 B‬, it has increased by 7.11% over the last week.
Yes, you can track EXELIXIS INC financials in yearly and quarterly reports right on TradingView.
EXELIXIS INC is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
EX9 earnings for the last quarter are 0.46 EUR per share, whereas the estimation was 0.41 EUR resulting in a 12.81% surprise. The estimated earnings for the next quarter are 0.34 EUR per share. See more details about EXELIXIS INC earnings.
EXELIXIS INC revenue for the last quarter amounts to ‪547.47 M‬ EUR, despite the estimated figure of ‪545.23 M‬ EUR. In the next quarter, revenue is expected to reach ‪456.84 M‬ EUR.
EX9 net income for the last quarter is ‪135.10 M‬ EUR, while the quarter before that showed ‪105.96 M‬ EUR of net income which accounts for 27.51% change. Track more EXELIXIS INC financial stats to get the full picture.
No, EX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 11, 2025, the company has ‪1.15 K‬ employees. See our rating of the largest employees — is EXELIXIS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EXELIXIS INC EBITDA is ‪694.30 M‬ EUR, and current EBITDA margin is 33.14%. See more stats in EXELIXIS INC financial statements.
Like other stocks, EX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EXELIXIS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EXELIXIS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EXELIXIS INC stock shows the buy signal. See more of EXELIXIS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.